A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Development of tau-based therapies for Alzheimer’s disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly i...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nature Medicine Ročník 26; číslo 3; s. 398 - 407
Hlavní autori: Barthélemy, Nicolas R., Li, Yan, Joseph-Mathurin, Nelly, Gordon, Brian A., Hassenstab, Jason, Benzinger, Tammie. L. S., Buckles, Virginia, Fagan, Anne M., Perrin, Richard J., Goate, Alison M., Morris, John C., Karch, Celeste M., Xiong, Chengjie, Allegri, Ricardo, Mendez, Patricio Chrem, Berman, Sarah B., Ikeuchi, Takeshi, Mori, Hiroshi, Shimada, Hiroyuki, Shoji, Mikio, Suzuki, Kazushi, Noble, James, Farlow, Martin, Chhatwal, Jasmeer, Graff-Radford, Neill R., Salloway, Stephen, Schofield, Peter R., Masters, Colin L., Martins, Ralph N., O’Connor, Antoinette, Fox, Nick C., Levin, Johannes, Jucker, Mathias, Gabelle, Audrey, Lehmann, Sylvain, Sato, Chihiro, Bateman, Randall J., McDade, Eric
Médium: Journal Article Magazine Article
Jazyk:English
Vydavateľské údaje: New York Nature Publishing Group US 01.03.2020
Nature Publishing Group
Predmet:
ISSN:1078-8956, 1546-170X, 1546-170X, 1744-7933
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Development of tau-based therapies for Alzheimer’s disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer’s disease. We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time. These tau phosphorylation state changes are uniquely associated with structural, metabolic, neurodegenerative and clinical markers of disease, and some (p-tau217 and p-tau181) begin with the initial increases in aggregate amyloid-β as early as two decades before the development of aggregated tau pathology. Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to symptom onset. These findings provide insights into the pathways linking tau, amyloid-β and neurodegeneration, and may facilitate clinical trials of tau-based treatments. Site-specific hyperphosphorylations of tau in the cerebrospinal fluid change with disease course, and correlate with pathology and cognitive decline in dominantly inherited Alzheimer’s disease.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMCID: PMC7309367
A list of members and affiliations appears at the end of the paper.
N.R.B. and C.S. performed the mass spectrometry analyses. Y.L., C.X., N.J.-M. and B.A.G. performed the statistical and imaging analyses. N.R.B., Y.L., R.J.B. and E.M. designed the study and wrote the initial draft of the manuscript. All authors collected samples and data, helped to interpret the results and reviewed drafts of the manuscript.
Author contributions
ISSN:1078-8956
1546-170X
1546-170X
1744-7933
DOI:10.1038/s41591-020-0781-z